Inventor · disambiguated record
Steven O'Neil
Also filed as: O'NEIL STEVEN · O'NEIL STEVEN R
7 granted patents·10 pending applications·9 citations·filing 2016–2025
78Inventor score
Top patents by PatentIndex Score
17 records- 0188US11524992B2Glypican-3-binding fibronectin based scaffold moleculesBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Dec 13, 2022·2 cites·12 claims
- 0281US10584160B2Glypican-3-binding fibronectin based scaffold moleculesBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Mar 10, 2020·3 cites·22 claims
- 0380US2025154261A1Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0479US12275791B2Multi-specific binding proteins that bind HER2, NKG2D, and CD16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Apr 15, 2025·1 cites·6 claims
- 0579US12215157B2Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Feb 4, 2025·1 cites·40 claims
- 0678US12492238B2Glypican-3-binding fibronectin based scaffold moleculesBRISTOL MYERS SQUIBB CO·Filed 2022·Granted Dec 9, 2025·0 cites·6 claims
- 0776US12384851B2Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Aug 12, 2025·1 cites·30 claims
- 0874US12378318B2Proteins binding NKG2D, CD16 and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Aug 5, 2025·1 cites·11 claims
- 0971US2022380459A1Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1063US2022089760A1Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1163US2025206827A1Multi-specific binding proteins that bind her2, nkg2d, and cd16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1256US2022195065A1Pharmaceutical formulations and dosage regimens for multi-specific binding proteins that bind her2, nkg2d, and cd16 for cancer treatmentDRAGONFLY THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1352US2024117054A1Proteins binding nkg2d, cd16 and flt3DRAGONFLY THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1450US2022025037A1Antibody variable domains targeting dll3, and use thereofDRAGONFLY THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1549US2023272041A1Formulation, Dosage Regimen, and Manufacturing Process for Heterodimeric FC-Fused ProteinsDRAGONFLY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1646US2021214436A1Multi-specific binding proteins and improvements thereonDRAGONFLY THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1744US2021221894A1Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tamsDRAGONFLY THERAPEUTICS INC·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Steven O'Neil files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →